Clinical Trial Update: Risk and Prevention Study: Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy of omega-3 polyunsaturated fatty acids (n-3 PUFA) in individuals at high cardiovascular risk has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases

Drugs mentioned

• Omega-3 polyunsaturated fatty acids (omega-3 polyunsaturated fatty acids)

Snippet

Sponsor: Mario Negri Institute for Pharmacological Research | Conditions: Cardiovascular Diseases | Phase 3 | Status: COMPLETED